TPIAO (recombinant human thrombopoietin) / 3SBio - LARVOL DELTA

Its core product TPIAO secured approval for a new indication; three novel drugs were successively approved for marketing... (The Manila Times) - "Amdokitug Injection (Yisaituo): Approved in February 2026 for the treatment of moderate-to-severe plaque psoriasis...Loncipoetin Alfa Injection (NuPIAO): Approved in March 2026 as the first domestic long-acting recombinant erythropoietin (EPO) biweekly formulation (a Class 1 innovative drug), indicated for hemodialysis patients with anemia caused by chronic kidney disease who are receiving erythropoietin therapy....Eltrombopag Ethanolamine Tablets: Approved in March 2026 for the treatment of immune thrombocytopenia (ITP) and severe aplastic anemia (SAA)."

China approval • Anemia • Aplastic Anemia • Immune Thrombocytopenic Purpura • Plaque Psoriasis

TE-ITP: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts (clinicaltrials.gov) - P4 | N=157 | Completed | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Active, not recruiting ➔ Completed

Trial completion • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura

TE-ITP: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts (clinicaltrials.gov) - P4 | N=157 | Active, not recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Jul 2024 | Trial primary completion date: Jun 2024 ➔ Feb 2024

Enrollment closed • Trial completion date • Trial primary completion date • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura

Circular: Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury (clinicaltrials.gov) - P4 | N=165 | Recruiting | Sponsor: The First Affiliated Hospital of Dalian Medical University | Trial primary completion date: Nov 2023 ➔ Apr 2024

Trial primary completion date • Hematological Disorders • Oncology • Thrombocytopenia

TE-ITP: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts (clinicaltrials.gov) - P4 | N=175 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura

TE-ITP: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts (clinicaltrials.gov) - P4 | N=175 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital

New P4 trial • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura

Circular: Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury (clinicaltrials.gov) - P4 | N=165 | Recruiting | Sponsor: The First Affiliated Hospital of Dalian Medical University | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Oncology • Thrombocytopenia

Circular: Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury (clinicaltrials.gov) - P4 | N=165 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Dalian Medical University

New P4 trial • Hematological Disorders • Oncology • Thrombocytopenia

Herombopag + rhTPO in Severe Immune Thrombocytopenia (clinicaltrials.gov) - P3 | N=90 | Recruiting | Sponsor: Yin Jie

New P3 trial • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura